Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...

In terms of pipeline development, the company reported positive results from the China bridging study of KarXT for schizophrenia and promising Phase 1 data for ZL-1310 in small cell lung cancer. Zai ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...

Given these trial results, there remains uncertainty about emraclidine’s future prospects and AbbVie’s ability to present a competitive alternative in the schizophrenia treatment market, particularly ...

The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Zai Lab (NASDAQ:ZLAB) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The FDA approved KarXT for schizophrenia in September. The drug will ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to IQVIA RDS (India) for conducting the trial of KarXT, ...